2017
The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma
Schutt CA, Mirandola L, Figueroa JA, Nguyen DD, Cordero J, Bumm K, Judson BL, Chiriva-Internati M. The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma. Oncotarget 2017, 5: 100280-100287. PMID: 29245977, PMCID: PMC5725019, DOI: 10.18632/oncotarget.22213.Peer-Reviewed Original ResearchNeck squamous cell carcinomaAutologous dendritic cellsAutologous tumor cellsSquamous cell carcinomaHNSCC patientsCancer-testis antigensDendritic cellsCell carcinomaNon-small cell lung cancerTumor cellsSp17 expressionIdeal immunotherapeutic targetSpecific cytotoxic lymphocytesCell lung cancerCurrent treatment modalitiesPotential serological biomarkerSperm protein 17Possible future targetsTherapeutic vaccinesImmunotherapeutic targetPoor prognosisAggressive malignancyMultiple myelomaPeripheral bloodTNM stage
2016
Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma
Kuo P, Manes RP, Schwam ZG, Judson BL. Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma. Otolaryngology 2016, 156: 132-136. PMID: 27703092, DOI: 10.1177/0194599816670146.Peer-Reviewed Original ResearchConceptsSinonasal undifferentiated carcinomaCombined modality therapyNational Cancer DatabaseUndifferentiated carcinomaChemoradiotherapy groupModality therapyOverall survivalSurvival outcomesTreatment modalitiesCancer DatabaseSurvival rateAdjuvant chemotherapy groupImproved survival outcomesMultivariate Cox regressionCumulative survival rateKaplan-Meier analysisMulti-institutional studyCases of SNUCAdjuvant chemotherapyChemotherapy groupMultimodality therapyModality treatmentPrognostic factorsCox regressionAggressive malignancy